Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed COO
STEMLINE THERAPEUTICS INC (STML) Create: Alert

All | News | Filings
Date FiledTypeDescription
03/13/2020 8-K Quarterly results
11/07/2019 8-K Quarterly results
08/02/2019 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Second Quarter 2019 Financial Results"
05/10/2019 8-K Quarterly results
Docs: "Stemline Therapeutics Reports First Quarter 2019 Financial Results"
03/15/2019 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Fourth Quarter 2018 Financial Results NEW YORK, Mar. 15, 2019 — Stemline Therapeutics, Inc. , a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today financial results for the quarter ended December 31, 2018. The Company also reviewed recent milestones: ELZONRIS™ — US Approval and Commercial Launch"
11/08/2018 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Third Quarter 2018 Financial Results NEW YORK, November 8, 2018 — Stemline Therapeutics, Inc. , a biopharmaceutical company focused on the development and potential commercialization of novel oncology therapeutics, announced today financial results for the quarter ended September 30, 2018. The Company also reviewed recent clinical and regulatory events, and outlined key upcoming milestones: ELZONRIS — Potential Approval and Pre-Commercial Activities"
08/09/2018 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Second Quarter 2018 Financial Results"
05/10/2018 8-K Quarterly results
Docs: "Stemline Therapeutics Reports First Quarter 2018 Financial Results NEW YORK, May 9, 2018 — Stemline Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today financial results for the quarter ended March 31, 2018. The Company also reviewed recent clinical and regulatory events, and outlined key upcoming milestones: SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm"
03/16/2018 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Fourth Quarter 2017 Financial Results"
11/09/2017 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Third Quarter 2017 Financial Results , November 9, 2017 —Stemline Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today financial results for the quarter ended September 30, 2017. The Company also reviewed recent clinical and regulatory events, and outlined key upcoming milestones: Pivotal Trial of SL-401 In Blastic Plasmacytoid Dendritic Cell Neoplasm"
08/08/2017 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Second Quarter 2017 Financial Results , August 8, 2017 —Stemline Therapeutics, Inc. , a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced today financial results for the quarter ended June 30, 2017. The Company also reviewed recent clinical and regulatory events, and outlined key upcoming milestones: SL-401 In Blastic Plasmacytoid Dendritic Cell Neoplasm"
05/10/2017 8-K Form 8-K - Current report
03/17/2017 8-K Form 8-K - Current report
11/08/2016 8-K Quarterly results
Docs: "Stemline Therapeutics Reports Third Quarter 2016 Financial Results and Highlights Recent Regulatory and Clinical Progress"
08/04/2016 8-K Form 8-K - Current report
05/09/2016 8-K Form 8-K - Current report
03/14/2016 8-K Form 8-K - Current report
11/06/2015 8-K Form 8-K - Current report
08/10/2015 8-K Form 8-K - Current report
05/11/2015 8-K Form 8-K - Current report
03/13/2015 8-K Form 8-K - Current report
11/12/2014 8-K Form 8-K - Current report

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy